Brief: I-Mab Partner Morphosys Announces New License Agreements For Felzartamab And Tj210
15/06/2022 13:54
June 15 (Reuters) - I-Mab IMAB.O :
* I-MAB PARTNER MORPHOSYS ANNOUNCES NEW LICENSE AGREEMENTS
FOR
FELZARTAMAB AND TJ210
* I-MAB - HIBIO TO OBTAIN EXCLUSIVE RIGHTS TO DEVELOP &
COMMERCIALIZE FELZARTAMAB ACROSS ALL INDICATIONS WORLDWIDE,
EXCLUDING GREATER CHINA
* I-MAB - HIBIO TO OBTAIN EXCLUSIVE RIGHTS TO DEVELOP &
COMMERCIALIZE TJ210 ACROSS ALL INDICATIONS WORLDWIDE, EXCLUDING
GREATER CHINA & SOUTH KOREA
Source text for Eikon: ID:nPnmqxDya
Further company coverage: IMAB.O
((reuters.briefs@thomsonreuters.com;))
Recent news on NovaBridge Biosciences
See all newsBrief: Visara Secures Exclusive Option For Potential Acquisition Of Yol104-2 For Ocular Surface Squamous Neoplasia
Brief: Visara Expands Ophthalmology Pipeline With Exclusive License For Investigational Nerve Growth Factor Therapy For Neurotrophic Keratitis
Brief: Wuhan Hiteck Biological Pharma Grants Visara Exclusive Rights To HT006.2.2 Outside Greater China
Brief: Novabridge Biosciences Announces Expanded Givastomig Safety And Efficacy Data
NovaBridge Biosciences expected to post a loss of 13 cents a share - Earnings Preview